The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving rat

Journal of Neurochemistry

Volumn 75, Issue 3, 2000, Pages 1147-1154

  Cartmell, Jayne ^a   Perry, Kenneth W ^a   Salhoff, Craig R ^a   Monn, James A ^a   Schoepp, Darryle D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Clozapine; LY379268; Metabotropic glutamate receptor; Microdialysis

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 5 HYDROXYINDOLEACETIC ACID; CLOZAPINE; DOPAMINE; EGLUMETAD; GLUTAMATE RECEPTOR ANTAGONIST; HOMOVANILLIC ACID; METABOTROPIC RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN BLOOD FLOW; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG POTENCY; EVOKED RESPONSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MICRODIALYSIS; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; AMINO ACIDS; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CLOZAPINE; DOPAMINE; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; HOMOVANILLIC ACID; HYDROXYINDOLEACETIC ACID; KINETICS; MALE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; XANTHENES;

EID: 0033844761     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2000.0751147.x     Document Type: Article

References (30)

1. Prefrontal dopamine and defect symptoms in schizophrenia
2. Regional differences in homovanillic acid concentrations after acute and chronic administration of antipsychotic drugs
3. Effects of clozapine, thioridazine, perpaline and haloperidol on the metabolism of the biogenic amines in the brain of the rat
4. The mGlu2/3 receptor agonists, LY354740 and LY379268, selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats
5. Monoamine metabolites: Their relationship and lack of relationship to monoaminergic neuronal activity
6. Pharmacology and functions of metabotropic glutamate receptors
7. Homovanillic acid concentrations in brain, CSF and plasma as indicators of central dopamine function in primates
8. Risperidone: Regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain
9. 2-adrenoceptor antagonism
10. The effects of clozapine and fluperlapine on the in vivo release and metabolism of dopamine in the striatum and in the prefrontal cortex of the freely moving rat
11. Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia
12. LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors
13. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum
14. Low HVA and normal 5HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: Correlations to symptomatology and family history
15. Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol
16. Reversal of phencyclidine effects by a group II metabotropic receptor agonist in rats
17. Design, synthesis and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: A potent, selective, systemically active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties
18. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): Identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors
19. Effect of lesions in the striatum, nucleus accumbens and medial raphe on phencyclidine-induced stereotyped behaviors and hyperactivity in rats
20. Phencyclidine-induced stereotyped behaviors in rats following specific neurotoxin lesions of the striatum
21. Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex
22. Effect of a tetrodotoxin pulse on dopamine and serotonin synthesis and metabolism in rat striatum as determined by microdialysis
23. Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum
24. New perspectives for the development of selective metabotropic glutamate receptor ligands
25. Effect of clozapine on the metabolism of serotonin in rat brain
26. Pharmacological agents acting at subtypes of metabotropic glutamate receptors
27. BIMG 80, a novel potential antipsychotic drug: Evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex
28. Schizophrenia and the frontal lobe
29. Sequence and significance of dopamine metabolism in the rat brain
30. Brain region effects of clozapine on amino acid and monoamine transmission